ArticleBMC cancer2019

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Hans Salwender et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.